5-BrdU (Broxuridine) , a nucleoside analog, are used in the detection of proliferating cells and competes with thymidine for incorporation into DNA.

在RG2大鼠神经胶质瘤细胞中，5-BrdU引起癌细胞系和癌干细胞群体扩展的逐渐抑制，且此抑制作用随剂量增加而增强。在H9细胞和BJ成纤维细胞中，5-BrdU改变了细胞周期分布。[1] BrdU稳定集成到DNA中，因此可用于评估细胞增殖和其他细胞过程。[2]

在大鼠胶质瘤RG2肿瘤模型中，Bromodeoxyuridine（300 mg/kg，i.p.或0.8 mg/ml，p.o.）显著减缓肿瘤进展。[1]

Assays are run in the presence of 100 μM ATP using 10 μM of substrate. 30 μL PROTEIN-MIX in 25% DMSO and incubated for 15 min at room temperature. 10 μL PEPTIDE-MIX is added, the mixture is incubated for 60 min at RT and stopped by adding 180 μL 6.4% TCA (final concentration: 5%). Incorporated phosphate is measured in a scintillation counter and IC50 values are calculated using a sigmoidal curve analysis program with variable hill slope[1].

Cultures are initially plated at 2000 cells/cm2 and are quantified with a Z2 Coulter Counter. RG2 rat glioma cells are treated once with 0, 1, 10, or 50 μM BrdU for 24 hours, and cumulative growth curves were obtained over 18 days. Control and treated cells are quantified and replated at equal densities on days 5, 12, and 18 after treatment.(Only for Reference)